Computer-aided approaches reveal trihydroxychroman and pyrazolone derivatives as potential inhibitors of SARS-CoV-2 virus main protease
Abstract COVID-19 was declared a pandemic by the World Health Organization (WHO) in March 2020. The disease is caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). The aim of this study is to target the SARS-CoV-2 virus main protease ($ M^{pro} $) via structure-based virtual screening. Consequently, > 580,000 ligands were processed via several filtration and docking steps, then the top 21 compounds were analysed extensively via MM-GBSA scoring and molecular dynamic simulations. Interestingly, the top compounds showed favorable binding energies and binding patterns to the protease enzyme, forming interactions with several key residues. Trihydroxychroman and pyrazolone derivatives, SN02 and SN18 ligands, exhibited very promising binding modes along with the best MM-GBSA scoring of –40.9 and –41.2 kcal $ mol^{−1} $, resp. MD simulations of 300 ns for the ligand-protein complexes of SN02 and SN18 affirmed the previously attained results of the potential inhibition activity of these two ligands. These potential inhibitors can be the starting point for further studies to pave way for the discovery of new antiviral drugs for SARS-CoV-2..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2020 |
|---|---|
| Erschienen: |
2020 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:71 |
|---|---|
| Enthalten in: |
Acta pharmaceutica - 71(2020), 3 vom: 31. Dez., Seite 325-333 |
| Beteiligte Personen: |
Atatreh, Noor [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| BKL: |
|---|
| Anmerkungen: |
© 2021 Noor Atatreh et al., published by Sciendo |
|---|
| doi: |
10.2478/acph-2021-0040 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
GRUY007650493 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | GRUY007650493 | ||
| 003 | DE-627 | ||
| 005 | 20230811152059.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230811s2020 xx |||||o 00| ||und c | ||
| 024 | 7 | |a 10.2478/acph-2021-0040 |2 doi | |
| 035 | |a (DE-627)GRUY007650493 | ||
| 035 | |a (DE-B1597)acph-2021-0040-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 084 | |a 44.40 |2 bkl | ||
| 100 | 1 | |a Atatreh, Noor |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Computer-aided approaches reveal trihydroxychroman and pyrazolone derivatives as potential inhibitors of SARS-CoV-2 virus main protease |
| 264 | 1 | |c 2020 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © 2021 Noor Atatreh et al., published by Sciendo | ||
| 520 | |a Abstract COVID-19 was declared a pandemic by the World Health Organization (WHO) in March 2020. The disease is caused by severe acute respiratory syndrome coronavirus 2 (SARSCoV-2). The aim of this study is to target the SARS-CoV-2 virus main protease ($ M^{pro} $) via structure-based virtual screening. Consequently, > 580,000 ligands were processed via several filtration and docking steps, then the top 21 compounds were analysed extensively via MM-GBSA scoring and molecular dynamic simulations. Interestingly, the top compounds showed favorable binding energies and binding patterns to the protease enzyme, forming interactions with several key residues. Trihydroxychroman and pyrazolone derivatives, SN02 and SN18 ligands, exhibited very promising binding modes along with the best MM-GBSA scoring of –40.9 and –41.2 kcal $ mol^{−1} $, resp. MD simulations of 300 ns for the ligand-protein complexes of SN02 and SN18 affirmed the previously attained results of the potential inhibition activity of these two ligands. These potential inhibitors can be the starting point for further studies to pave way for the discovery of new antiviral drugs for SARS-CoV-2. | ||
| 700 | 1 | |a Hasan, Shaima |4 aut | |
| 700 | 1 | |a Ali, Bassam R. |4 aut | |
| 700 | 1 | |a Ghattas, Mohammad A. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Acta pharmaceutica |d Sciendo, 1997 |g 71(2020), 3 vom: 31. Dez., Seite 325-333 |h Online-Ressource |w (DE-627)GRUY000481424 |w (DE-600)2255569-9 |w (DE-576)281323526 |x 1846-9558 |7 nnns |
| 773 | 1 | 8 | |g volume:71 |g year:2020 |g number:3 |g day:31 |g month:12 |g pages:325-333 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.2478/acph-2021-0040 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_GRUY | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OPC-PHA | ||
| 936 | b | k | |a 44.40 |j Pharmazie |j Pharmazeutika |q VZ |
| 951 | |a AR | ||
| 952 | |d 71 |j 2020 |e 3 |b 31 |c 12 |h 325-333 | ||